On September 2, 2021 Evotec partner Kazia Therapeutics Limited ("Kazia", ASX: KZA; NASDAQ: KZIA) reported that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé ("ANSM"), the French regulatory agency (Press release, Evotec, SEP 2, 2021, View Source;announcements/press-releases/p/evotec-partner-kazia-therapeutics-announces-full-regulatory-approval-for-phase-i-study-of-evt801-6092 [SID1234587161]). The study is expected to open to recruitment by the end of CY2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Evotec and Kazia entered into both a licensing and master service agreement in April 2021. Under the contract, Evotec grants Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801, a small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec’s partnership with Sanofi.
Kazia CEO, Dr James Garner, commented: "since concluding our license agreement with Evotec in April, we have made exceptionally swift progress in bringing EVT801 to the clinic. We have been grateful for the exceptional efforts of the Evotec team, working closely with Kazia colleagues to drive the project forward. The study that we have designed is highly innovative, which befits the rich potential of EVT801, and we look forward to commencing recruitment in the near future."